{"organizations": [], "uuid": "ad081936f3e4e755acc16730b37a96a43a178301", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-acelrx-announces-completion-of-the/brief-acelrx-announces-completion-of-the-human-factors-study-for-dsuvia-and-confirms-plans-to-resubmit-nda-idUSFWN1RT0H8", "country": "US", "domain_rank": 408, "title": "BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T14:04:00.000+03:00", "replies_count": 0, "uuid": "ad081936f3e4e755acc16730b37a96a43a178301"}, "author": "", "url": "https://www.reuters.com/article/brief-acelrx-announces-completion-of-the/brief-acelrx-announces-completion-of-the-human-factors-study-for-dsuvia-and-confirms-plans-to-resubmit-nda-idUSFWN1RT0H8", "ord_in_thread": 0, "title": "BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA", "locations": [], "entities": {"persons": [{"name": "dsu", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "nda", "sentiment": "negative"}, {"name": "acelrx pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "nda reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 06 AM / Updated 10 minutes ago BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA Reuters Staff 1 Min Read \nApril 16 (Reuters) - AcelRx Pharmaceuticals Inc: \n* ACELRX ANNOUNCES COMPLETION OF THE HUMAN FACTORS STUDY FOR DSUVIA AND CONFIRMS PLANS TO RESUBMIT NDA IN Q2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-16T14:04:00.000+03:00", "crawled": "2018-04-16T14:21:23.012+03:00", "highlightTitle": ""}